Trial Profile
PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- 11 Oct 2016 Results (n=36) assessing preliminary safety and efficacy presented at the 41st European Society for Medical Oncology Congress.
- 03 Aug 2016 New trial record
- 07 Jun 2016 Interim results (n=29) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology